Rasmus Møller

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6440064/publications.pdf

Version: 2024-02-01

1039880 1474057 4,473 9 9 9 citations h-index g-index papers 13 13 13 12180 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell, 2020, 181, 1036-1045.e9.	13.5	3,572
2	A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics. Nature Biomedical Engineering, 2021, 5, 815-829.	11.6	228
3	Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity. Immunity, 2021, 54, 557-570.e5.	6.6	153
4	SARS-CoV-2 infection in hamsters and humans results in lasting and unique systemic perturbations after recovery. Science Translational Medicine, 2022, 14, .	5.8	129
5	SARS-CoV-2 infects human adult donor eyes and hESC-derived ocular epithelium. Cell Stem Cell, 2021, 28, 1205-1220.e7.	5. 2	44
6	Common Genetic Variation in Humans Impacts InÂVitro Susceptibility to SARS-CoV-2 Infection. Stem Cell Reports, 2021, 16, 505-518.	2.3	39
7	Cardiomyocytes recruit monocytes upon SARS-CoV-2 infection by secretingÂCCL2. Stem Cell Reports, 2021, 16, 2274-2288.	2.3	37
8	Immune memory from SARS-CoV-2 infection in hamsters provides variant-independent protection but still allows virus transmission. Science Immunology, 2021, 6, eabm3131.	5.6	37
9	miRNA-mediated targeting of human cytomegalovirus reveals biological host and viral targets of IE2. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 1069-1074.	3.3	31